We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 29, 2022

Effects of Tirzepatide vs Insulin Glargine on Kidney Outcomes in Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Lancet Diabetes Endocrinol 2022 Sep 21;[EPub Ahead of Print], HJL Heerspink, N Sattar, I Pavo, A Haupt, KL Duffin, Z Yang, RJ Wiese, KR Tuttle, DZI Cherney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading